Extended release erythromycin derivatives
CA 2425688 A1 · Owner: Advancis Pharmaceutical Corporation · Inventors: Treacy, Donald, J. Jr.; Rudnic, Edward M.; Wassink, Sandra E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An extended release pharmaceutical composition comprised of an erythromycin derivative and non-polymer material for providing for extended release in , particular, a member selected from the group consisting of clays long chain , hydrocarbons, long chain carboxylic acids long chain carboxylic acid esters, long chain alcohols and mixtures thereof, with said member being present in an amount to provide for extended release of the erythromycin derivative.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 12, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.